SITE MAP

What's on this site?

    Indication

    Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

    Important Safety Information

    • Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.

    • In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.

    • To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.

    • Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.

    • Safety and efficacy in pediatric patients below the age of 17 years have not been established.

    Click here for Full Prescribing Information.